Bredesen Protocol Overview 2017-01-25T11:47:44-08:00

What We Are

Of the 318 million Americans currently living, 45 million will develop Alzheimer’s disease during their lifetimes if we do not do something to prevent and reverse cognitive decline. Many others will suffer from vascular dementia or Lewy body dementia or other forms of dementia. Loss of mental faculties has become the #1 concern of aging Americans.

Medicine is undergoing a radical transformation, from 20th-century medicine to 21st-century medicine: 20th-century medicine uses small data sets—like looking at sodium and potassium but not the genome or metabolome or epigenome—to attempt to diagnose very complex illnesses in very complicated organisms—human beings. 20th-century medicine makes a diagnosis of what—Alzheimer’s or cardiovascular disease or hypertension—without understanding why. 20th-century medicine uses a one-size-fits-all, monotherapeutic approach, and has been largely unsuccessful in treating chronic illnesses such as Alzheimer’s disease, other neurodegenerative conditions, cancer, and cerebrovascular disease.

21st-century medicine is completely different: larger data sets are used to identify network changes that characterize chronic illnesses, revealing the “why” for each person—this is the etiodiagnosis. Prevention and early symptomatic approaches are emphasized. Addressing the cause of each condition in a comprehensive and personalized, programmatic way leads to improved outcomes, and each program is repeatedly optimized over time, to ensure sustained improvement.

Such an approach was used to bring about the first reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), published in 2014 (Bredesen, Aging 2014). MPI Cognition was established to provide the research, support, and information to make this approach available to all. We have identified multiple subtypes of Alzheimer’s disease using the extensive metabolic profiling of 21st-century medicine (Bredesen, Aging 2015), identified new and previously unrecognized causes of Alzheimer’s disease (Aging 2016), and developed a continuously evolving version of Dr. Bredesen’s original MEND program. We hope that this information, research, and support will be valuable to all in our shared goal of reducing the global burden of dementia.  

MPI Cognition is the beginning
What Is Needed Is…

…a coordinated, global effort to reduce dementia everywhere

…an extensive network of practitioners who are experts in 21st-century medicine

…education so that people know to seek help when the earliest symptoms appear rather than waiting in denial until late in the course of cognitive decline

…ready access to appropriate laboratory testing and personalized, optimally effective programs

…to continue to optimize The Bredesen Protocol, increasing efficiency and applying appropriate variations to other neurodegenerative diseases. MPI Cognition is the beginning of the end of Alzheimer’s disease as a major, ineluctable problem.

What We Provide

Blurred image of female participant

67-year-old woman with 2-year history
of progressive cognitive decline

  • Mother died with dementia, onset age 62.
  • Unable to navigate on freeway.
  • Could not remember what she had read.
  • Unable to prepare reports for work.
  • Unable to recall even 4-digit numbers.
  • Retinal scan positive for amyloid (greater than London pt.).
  • Treated with MEND (Metabolic Enhancement for NeuroDegeneration)
  • Cognitive decline reversed, able to work full-time, memory better than in decades
Blurred image of elderly male

70-year-old man with 12-year history
of accelerating memory loss

  • ApoE4 positive
  • FDG-PET scan typical of Alzheimer’s disease
  • Neuropsych testing 2003, 2007, 2013
  • Progressive loss: CVLT from 84%ile to 1%ile
  • Unable to remember lock combination, faces, schedule
  • Difficulty at work, and with numbers; early Alzheimer’s disease
  • Improvement at 6 months: co-workers, schedule, faces, numbers
  • Wife notes accelerated decline completely stopped
  • Follow-up neuropsychological testing showed marked improvement
Blurred photo of female participant

55-year-old attorney with 4-year history
of severe memory loss

  • Left stove on multiple times when leaving home
  • Recorded conversations since she could not remember
  • Carried iPad to note everything
  • Unable to practice or to learn new information
  • Lost mid-sentence; had a talk with her children
  • Iterative Rx returned her to normal over 10 mos
  • Back at work, learning new areas of law, and learned Spanish
  • iPad optional